AbbVie’s Parkinson’s Plans Back In The PINK With Mitokinin Buy

 
• By Kevin Grogan

Just over six months after getting a complete response letter for its prodrug carbidopa and levodopa combination product, the US major has acquired Mitokinin and its selective PINK1 activator which could potentially be a disease-modifying treatment for Parkinson’s disease.

• Source: Shutterstock

More from Deals

More from Business